<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520920</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-213</org_study_id>
    <secondary_id>CTR20170965</secondary_id>
    <nct_id>NCT03520920</nct_id>
  </id_info>
  <brief_title>BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)</brief_title>
  <official_title>A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a multicenter, open-label, phase 2 study to evaluate efficacy, safety, and&#xD;
      tolerability of BGB-3111 (zanubrutinib) 160 milligrams (mg) twice daily (BID) in combination&#xD;
      with rituximab in Chinese participants with relapsed/refractory (R/R) diffuse large B-cell&#xD;
      lymphoma (DLBCL) (non-GCB [non-germinal center B-cell-like] subtype) and R/R indolent&#xD;
      lymphoma (follicular lymphoma [FL] and marginal zone lymphoma [MZL]).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2018</start_date>
  <completion_date type="Actual">August 28, 2020</completion_date>
  <primary_completion_date type="Actual">August 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) As Measured By The Investigator</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>The percentage of participants whose best overall response met partial response (PR) or complete response (CR) criteria among all participants. The 95% confidence interval (CI) was calculated with the Clopper-Pearson method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR) As Determined By Investigator</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR: Event-free Rate</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) As Determined By Investigator</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS: Event-free Rate</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS: Survival Rate</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Survival rates were estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Response (TTR) As Determined By The Investigator</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median TTR</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate As Determined By The Investigator</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>The percentage of participants whose best overall response met complete response or complete metabolic response criteria among all participants are reported. The 95% CI was calculated with Clopper-Pearson method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) And Serious TEAEs</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
    <description>A treatment-emergent adverse event was defined as an adverse event with an onset or worsening (if present pretreatment) starting on or after the first dose of study drug up to 30 days after discontinuation of zanubrutinib or 90 days after discontinuation of rituximab, whichever occurred later; or initiation of new anticancer therapy if it occurred prior to the other 2 dates. Worsening of a treatment-emergent adverse event to Grade 5 beyond Day 30 after the last dose of zanubrutinib or Day 90 after the last dose rituximab was also considered a treatment-emergent adverse event if the event occurred prior to initiation of new anticancer therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>R/R Non-GCB DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R/R FL or MZL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with R/R FL or MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>Administered zanubrutinib 160 mg orally (PO) BID continuously</description>
    <arm_group_label>R/R FL or MZL</arm_group_label>
    <arm_group_label>R/R Non-GCB DLBCL</arm_group_label>
    <other_name>BGB-3111</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Administered rituximab 375 mg/m^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
    <arm_group_label>R/R FL or MZL</arm_group_label>
    <arm_group_label>R/R Non-GCB DLBCL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. ≥ Age 18 years at time of signing of informed consent.&#xD;
&#xD;
          2. Measurable disease by computed tomography (CT) or positron emission tomography/CT or&#xD;
             magnetic resonance imaging, defined as ≥1 nodal lesion that was &gt;1.5 centimeters (cm)&#xD;
             in the longest diameter, or ≥1 extra-nodal lesion (for example, hepatic nodules) that&#xD;
             was &gt;1 cm in the longest diameter.&#xD;
&#xD;
          3. Availability of archival or fresh tumor tissue sample from an evaluable core or&#xD;
             excisional biopsy.&#xD;
&#xD;
          4. Participants meet the following criteria:&#xD;
&#xD;
               1. Cohort 1: R/R non-GCB DLBCL i. Histologically confirmed non-GCB DLBCL per Hans&#xD;
                  criteria with non-transformed disease; additional methodologies for confirming&#xD;
                  non-GCB DLBCL may have been considered in consultation with the medical monitor.&#xD;
                  ii. Relapsed disease (disease progression after most recent therapy for DLBCL&#xD;
                  occurring more than 6 months after the completion of last therapy) or refractory&#xD;
                  disease (failure to achieve complete response [CR] or partial response [PR] to&#xD;
                  therapy for non-GCB DLBCL or disease progression within 6 months after completion&#xD;
                  of the most recent therapy for non-GCB DLBCL). iii. Must have received at least&#xD;
                  one standard anthracycline ± rituximab-based treatment (for example, rituximab&#xD;
                  plus cyclophosphamide, doxorubicin [or epirubicin, hydroxydaunorubicin, or&#xD;
                  similar], vincristine, and prednisone) or cyclophosphamide, vincristine, and&#xD;
                  prednisone +/- rituximab for DLBCL.&#xD;
&#xD;
               2. Cohort 2: R/R FL or R/R MZL i. Histologically confirmed CD20+ FL (Grade 1, 2, or&#xD;
                  3a) or MZL. ii. Relapsed disease (disease progression after most recent therapy&#xD;
                  for FL or MZL occurring more than 6 months after the completion of last therapy)&#xD;
                  or refractory disease (failure to achieve complete response (CR) or partial&#xD;
                  response (PR) to most recent therapy for FL or MZL, or disease progression within&#xD;
                  6 months after completion of the most recent therapy for FL or MZL).&#xD;
&#xD;
          5. Laboratory parameters as specified below:&#xD;
&#xD;
               1. Hematologic: Platelet count ≥75 x 10^9/liter (L) independent of growth factor or&#xD;
                  transfusion within 7 days of study entry; absolute neutrophil count (ANC) ≥1 x&#xD;
                  10^9/L independent of growth factor within 7 days of study entry, hemoglobin &gt;8&#xD;
                  grams/deciliter within 7 days of study entry.&#xD;
&#xD;
               2. Hepatic: Total bilirubin ≤ 2x upper limit of normal (ULN) unless documented&#xD;
                  Gilbert's syndrome; aspartate aminotransferase/serum glutamic-oxaloacetic&#xD;
                  transaminase and alanine transaminase/serum glutamic-pyruvic transaminase ≤3x&#xD;
                  ULN.&#xD;
&#xD;
               3. Renal: Creatinine clearance ≥30 milliliters/minute (as estimated by the&#xD;
                  Cockcroft-Gault equation based on ideal body weight or as measured by nuclear&#xD;
                  medicine scan or 24-hour urine collection).&#xD;
&#xD;
               4. International normalized ratio and activated partial thromboplastin time ≤1.5x&#xD;
                  ULN. Participants with anti-phospholipid syndrome, acquired von Willebrand&#xD;
                  disease, factor inhibitors or on vitamin K antagonist may have been enrolled&#xD;
                  after discussion with the Medical Monitor.&#xD;
&#xD;
          6. Left ventricular ejection fraction ≥50%.&#xD;
&#xD;
          7. Life expectancy ≥6 months.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group performance status of 0, 1, or 2.&#xD;
&#xD;
          9. Female participants of childbearing potential must have practiced highly effective&#xD;
             methods of contraception initiated prior to first dose of study drug, for the duration&#xD;
             of the study, and for ≥90 days after the last dose of zanubrutinib, or 12 months after&#xD;
             the last dose of rituximab, whichever is longer.&#xD;
&#xD;
         10. Male participants were eligible if vasectomized or if they agreed to the use of&#xD;
             barrier contraception in combination with other methods above during the study&#xD;
             treatment period and for ≥90 days after the last dose of zanubrutinib.&#xD;
&#xD;
         11. Able to provide written informed consent and could understand and comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Known central nervous system lymphoma or leukemia.&#xD;
&#xD;
          2. Histological confirmed gastric mucosa-associated lymphoid tissue type MZL.&#xD;
&#xD;
          3. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.&#xD;
&#xD;
          4. Clinically significant cardiovascular disease.&#xD;
&#xD;
          5. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand&#xD;
             disease, or history of spontaneous bleeding requiring blood transfusion or other&#xD;
             medical intervention.&#xD;
&#xD;
          6. History of stroke or intracranial hemorrhage within 6 months before first dose of&#xD;
             study drug.&#xD;
&#xD;
          7. Severe or debilitating pulmonary disease.&#xD;
&#xD;
          8. Hypersensitivity reaction to zanubrutinib or rituximab or any of the other ingredients&#xD;
             of the study drugs.&#xD;
&#xD;
          9. Prior Bruton tyrosine kinase inhibitor treatment.&#xD;
&#xD;
         10. Required ongoing treatment with a strong cytochrome P450 protein inhibitor or inducer.&#xD;
&#xD;
         11. Vaccination with a live vaccine within 28 days of the first dose of study drug.&#xD;
&#xD;
         12. Hematopoietic stem cell transplantation within 6 months of first dose of study drug.&#xD;
&#xD;
         13. Receipt of the following treatment prior to first dose of study drug:&#xD;
&#xD;
               1. Corticosteroids at doses &gt;20 mg/day prednisone equivalent or steroids given with&#xD;
                  anti-neoplastic intent within 7 days prior to first dose of study drug.&#xD;
&#xD;
               2. Chemotherapy or radiotherapy within 4 weeks.&#xD;
&#xD;
               3. Monoclonal antibody within 4 weeks.&#xD;
&#xD;
               4. Investigational therapy within 4 weeks.&#xD;
&#xD;
               5. Chinese patent medicine with anti-neoplastic intent within 4 weeks.&#xD;
&#xD;
         14. Not recovered from toxicity of any prior anti-cancer therapy to ≤Grade 1, except for&#xD;
             alopecia, ANC, hemoglobin (Hgb), and platelets. For ANC, Hgb and platelets, see&#xD;
             inclusion criterion #5.&#xD;
&#xD;
         15. Prior malignancy within the past 3 years, except for curatively treated basal or&#xD;
             squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the&#xD;
             cervix or breast.&#xD;
&#xD;
         16. Unable to swallow capsules or disease significantly affecting gastrointestinal&#xD;
             function such as malabsorption syndrome, resection of the stomach or small bowel,&#xD;
             symptomatic inflammatory bowel disease, history of bariatric surgery, or partial or&#xD;
             complete bowel obstruction.&#xD;
&#xD;
         17. Major surgery within 4 weeks prior to first dose of study treatment.&#xD;
&#xD;
         18. Active fungal, bacterial and/or viral infection requiring systemic therapy.&#xD;
&#xD;
         19. Known infection with human immunodeficiency virus, or serologic status reflecting&#xD;
             active hepatitis B or C infection as follows:&#xD;
&#xD;
               1. Presence of hepatitis B surface antigen (HBsAg) or anti-hepatitis B core antibody&#xD;
                  (anti-HBc). Participants with presence of anti-HBc, but absence of HBsAg, were&#xD;
                  eligible if hepatitis B virus (HBV) DNA was &lt;500 international units (IU)/mL,&#xD;
                  anti-viral therapy started before the first dose of study treatment, and if they&#xD;
                  were willing to undergo monthly monitoring for HBV reactivation.&#xD;
&#xD;
               2. Presence of hepatitis C virus (HCV) antibody. Participants with presence of HCV&#xD;
                  antibody were eligible if HCV RNA was undetectable (&lt;15 IU/mL).&#xD;
&#xD;
         20. Pregnant or lactating women.&#xD;
&#xD;
         21. Underlying medical conditions that, in the investigator's opinion, would have rendered&#xD;
             the administration of study drug hazardous or obscure the interpretation of toxicity&#xD;
             or adverse events.&#xD;
&#xD;
         22. Concurrent participation in another therapeutic clinical trial.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may have applied.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College of HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Qingyuan Zhang, Rong Tao, Zhenyu Li, et al. Zanubrutinib (BGB-3111) in combination with rituximab in patients with relapsed/refractory Non-Hodgkin Lymphoma [EHA-2188].</citation>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <results_first_submitted>August 26, 2021</results_first_submitted>
  <results_first_submitted_qc>October 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 28, 2021</results_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03520920/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03520920/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 4 study centers in China, all of which enrolled participants. The first enrolled participants received their first dose on 04 January 2018, and the last participant enrolled received their first dose on 20 December 2018. A total of 41 participants with non-Hodgkin lymphoma (NHL) were enrolled into the study, and all received ≥1 dose of study treatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
          <description>Participants with relapsed/refractory (R/R) non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL) received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 milligrams (mg) orally (PO) twice daily (BID) continuously and rituximab 375 mg/meter squared (m^2) intravenously (IV) on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
        </group>
        <group group_id="P2">
          <title>Relapsed/Refractory Follicular Lymphoma</title>
          <description>Participants with R/R follicular lymphoma (FL) received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
        </group>
        <group group_id="P3">
          <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
          <description>Participants with R/R marginal zone lymphoma (MZL) received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by the Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
          <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
        </group>
        <group group_id="B2">
          <title>Relapsed/Refractory Follicular Lymphoma</title>
          <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
        </group>
        <group group_id="B3">
          <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
          <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="15.00"/>
                    <measurement group_id="B2" value="47.6" spread="12.36"/>
                    <measurement group_id="B3" value="61.2" spread="8.87"/>
                    <measurement group_id="B4" value="53.0" spread="13.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilogram/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.43" spread="2.652"/>
                    <measurement group_id="B2" value="25.04" spread="5.079"/>
                    <measurement group_id="B3" value="24.33" spread="4.813"/>
                    <measurement group_id="B4" value="24.17" spread="3.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area</title>
          <units>m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.72" spread="0.113"/>
                    <measurement group_id="B2" value="1.77" spread="0.295"/>
                    <measurement group_id="B3" value="1.69" spread="0.240"/>
                    <measurement group_id="B4" value="1.74" spread="0.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group Performance (ECOG)Status</title>
          <description>ECOG Performance Status - Grade 0 = Fully active, able to carry on all pre-disease performance without restriction; Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work, office work; Grade 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis B Core Antibody</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR) As Measured By The Investigator</title>
        <description>The percentage of participants whose best overall response met partial response (PR) or complete response (CR) criteria among all participants. The 95% confidence interval (CI) was calculated with the Clopper-Pearson method.</description>
        <time_frame>Up to approximately 2.5 years</time_frame>
        <population>Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab) on the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
            <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
          <group group_id="O2">
            <title>Relapsed/Refractory Follicular Lymphoma</title>
            <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
          <group group_id="O3">
            <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
            <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR) As Measured By The Investigator</title>
          <description>The percentage of participants whose best overall response met partial response (PR) or complete response (CR) criteria among all participants. The 95% confidence interval (CI) was calculated with the Clopper-Pearson method.</description>
          <population>Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab) on the study.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="15.4" upper_limit="59.2"/>
                    <measurement group_id="O2" value="56.3" lower_limit="29.9" upper_limit="80.2"/>
                    <measurement group_id="O3" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration Of Response (DOR) As Determined By Investigator</title>
        <description>The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.</description>
        <time_frame>Up to approximately 2.5 years</time_frame>
        <population>Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab) on the study. Duration of response was summarized for responders (participants with a best response of partial response or higher) only.</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
            <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
          <group group_id="O2">
            <title>Relapsed/Refractory Follicular Lymphoma</title>
            <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
          <group group_id="O3">
            <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
            <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration Of Response (DOR) As Determined By Investigator</title>
          <description>The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.</description>
          <population>Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab) on the study. Duration of response was summarized for responders (participants with a best response of partial response or higher) only.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.79" lower_limit="0.72" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="5.45" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="22.18" lower_limit="8.31" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DOR: Event-free Rate</title>
        <description>The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.</description>
        <time_frame>Up to approximately 2.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
            <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
          <group group_id="O2">
            <title>Relapsed/Refractory Follicular Lymphoma</title>
            <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
          <group group_id="O3">
            <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
            <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
        </group_list>
        <measure>
          <title>DOR: Event-free Rate</title>
          <description>The DOR was defined as the time from the date that the response criteria were first met to the date that progressive disease (PD) was objectively documented or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.</description>
          <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="11.1" upper_limit="80.4"/>
                    <measurement group_id="O2" value="88.9" lower_limit="43.3" upper_limit="98.4"/>
                    <measurement group_id="O3" value="100.0" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="11.1" upper_limit="80.4"/>
                    <measurement group_id="O2" value="77.8" lower_limit="36.5" upper_limit="93.9"/>
                    <measurement group_id="O3" value="66.7" lower_limit="5.4" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="11.1" upper_limit="80.4"/>
                    <measurement group_id="O2" value="64.8" lower_limit="25.3" upper_limit="87.2"/>
                    <measurement group_id="O3" value="66.7" lower_limit="5.4" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="4.6" upper_limit="67.6"/>
                    <measurement group_id="O2" value="51.9" lower_limit="16.4" upper_limit="78.8"/>
                    <measurement group_id="O3" value="66.7" lower_limit="5.4" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="4.6" upper_limit="67.6"/>
                    <measurement group_id="O2" value="51.9" lower_limit="16.4" upper_limit="78.8"/>
                    <measurement group_id="O3" value="66.7" lower_limit="5.4" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="33.3" lower_limit="0.9" upper_limit="77.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) As Determined By Investigator</title>
        <description>The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.</description>
        <time_frame>Up to approximately 2.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
            <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
          <group group_id="O2">
            <title>Relapsed/Refractory Follicular Lymphoma</title>
            <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
          <group group_id="O3">
            <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
            <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) As Determined By Investigator</title>
          <description>The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.</description>
          <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" lower_limit="2.69" upper_limit="5.49"/>
                    <measurement group_id="O2" value="11.10" lower_limit="5.49" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="24.87" lower_limit="11.01" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS: Event-free Rate</title>
        <description>The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.</description>
        <time_frame>Up to approximately 2.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
            <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
          <group group_id="O2">
            <title>Relapsed/Refractory Follicular Lymphoma</title>
            <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
          <group group_id="O3">
            <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
            <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS: Event-free Rate</title>
          <description>The PFS was defined as time from first dose of study treatment until first documentation of progression, assessed per the Lugano Classification, or death, whichever occurred first. The event-free rate was estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.</description>
          <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="4.3" upper_limit="37.7"/>
                    <measurement group_id="O2" value="73.3" lower_limit="43.3" upper_limit="89.1"/>
                    <measurement group_id="O3" value="100.0" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="4.3" upper_limit="37.7"/>
                    <measurement group_id="O2" value="66.7" lower_limit="37.5" upper_limit="84.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="4.3" upper_limit="37.7"/>
                    <measurement group_id="O2" value="46.7" lower_limit="21.2" upper_limit="68.7"/>
                    <measurement group_id="O3" value="80.0" lower_limit="20.4" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="4.3" upper_limit="37.7"/>
                    <measurement group_id="O2" value="46.7" lower_limit="21.2" upper_limit="68.7"/>
                    <measurement group_id="O3" value="60.0" lower_limit="12.6" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="2.0" upper_limit="30.7"/>
                    <measurement group_id="O2" value="40.0" lower_limit="16.5" upper_limit="62.8"/>
                    <measurement group_id="O3" value="60.0" lower_limit="12.6" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="2.0" upper_limit="30.7"/>
                    <measurement group_id="O2" value="40.0" lower_limit="16.5" upper_limit="62.8"/>
                    <measurement group_id="O3" value="60.0" lower_limit="12.6" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.</description>
        <time_frame>Up to approximately 2.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
            <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
          <group group_id="O2">
            <title>Relapsed/Refractory Follicular Lymphoma</title>
            <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
          <group group_id="O3">
            <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
            <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Medians were estimated by the Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.</description>
          <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.20" lower_limit="5.39" upper_limit="24.44"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS: Survival Rate</title>
        <description>The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Survival rates were estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.</description>
        <time_frame>Up to approximately 2.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
            <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
          <group group_id="O2">
            <title>Relapsed/Refractory Follicular Lymphoma</title>
            <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
          <group group_id="O3">
            <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
            <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance. Administered zanubrutinib 160 mg PO BID continuously and rituximab 375 mg/m^2 IV on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.</description>
          </group>
        </group_list>
        <measure>
          <title>OS: Survival Rate</title>
          <description>The OS was defined as the time from the date of first dose of study treatment to the date of death due to any cause. Survival rates were estimated by the Kaplan-Meier method with 95% CIs estimated using Greenwood's formula.</description>
          <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="46.3" upper_limit="87.6"/>
                    <measurement group_id="O2" value="93.3" lower_limit="61.3" upper_limit="99.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9" lower_limit="30.8" upper_limit="75.0"/>
                    <measurement group_id="O2" value="93.3" lower_limit="61.3" upper_limit="99.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="21.8" upper_limit="65.4"/>
                    <measurement group_id="O2" value="93.3" lower_limit="61.3" upper_limit="99.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" lower_limit="13.8" upper_limit="54.8"/>
                    <measurement group_id="O2" value="93.3" lower_limit="61.3" upper_limit="99.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" lower_limit="13.8" upper_limit="54.8"/>
                    <measurement group_id="O2" value="93.3" lower_limit="61.3" upper_limit="99.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" lower_limit="13.8" upper_limit="54.8"/>
                    <measurement group_id="O2" value="93.3" lower_limit="61.3" upper_limit="99.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="NA" upper_limit="NA">NA = Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time To Response (TTR) As Determined By The Investigator</title>
        <description>The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).</description>
        <time_frame>Up to approximately 2.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
            <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
          <group group_id="O2">
            <title>Relapsed/Refractory Follicular Lymphoma</title>
            <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
          <group group_id="O3">
            <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
            <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
        </group_list>
        <measure>
          <title>Time To Response (TTR) As Determined By The Investigator</title>
          <description>The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).</description>
          <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="2.054"/>
                    <measurement group_id="O2" value="6.15" spread="3.867"/>
                    <measurement group_id="O3" value="3.67" spread="1.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median TTR</title>
        <description>The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).</description>
        <time_frame>Up to approximately 2.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
            <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
          <group group_id="O2">
            <title>Relapsed/Refractory Follicular Lymphoma</title>
            <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
          <group group_id="O3">
            <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
            <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
        </group_list>
        <measure>
          <title>Median TTR</title>
          <description>The TTR was defined as the time from the date of the first dose of study treatment to the date of the first qualifying response (partial response or better).</description>
          <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" lower_limit="2.7" upper_limit="8.2"/>
                    <measurement group_id="O2" value="5.49" lower_limit="2.6" upper_limit="13.8"/>
                    <measurement group_id="O3" value="2.73" lower_limit="2.7" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response Rate As Determined By The Investigator</title>
        <description>The percentage of participants whose best overall response met complete response or complete metabolic response criteria among all participants are reported. The 95% CI was calculated with Clopper-Pearson method.</description>
        <time_frame>Up to approximately 2.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
            <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
          <group group_id="O2">
            <title>Relapsed/Refractory Follicular Lymphoma</title>
            <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
          <group group_id="O3">
            <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
            <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate As Determined By The Investigator</title>
          <description>The percentage of participants whose best overall response met complete response or complete metabolic response criteria among all participants are reported. The 95% CI was calculated with Clopper-Pearson method.</description>
          <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="1.2" upper_limit="31.7"/>
                    <measurement group_id="O2" value="18.8" lower_limit="4.0" upper_limit="45.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) And Serious TEAEs</title>
        <description>A treatment-emergent adverse event was defined as an adverse event with an onset or worsening (if present pretreatment) starting on or after the first dose of study drug up to 30 days after discontinuation of zanubrutinib or 90 days after discontinuation of rituximab, whichever occurred later; or initiation of new anticancer therapy if it occurred prior to the other 2 dates. Worsening of a treatment-emergent adverse event to Grade 5 beyond Day 30 after the last dose of zanubrutinib or Day 90 after the last dose rituximab was also considered a treatment-emergent adverse event if the event occurred prior to initiation of new anticancer therapy.</description>
        <time_frame>Up to approximately 2.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
        <group_list>
          <group group_id="O1">
            <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
            <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
          <group group_id="O2">
            <title>Relapsed/Refractory Follicular Lymphoma</title>
            <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
          <group group_id="O3">
            <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
            <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) And Serious TEAEs</title>
          <description>A treatment-emergent adverse event was defined as an adverse event with an onset or worsening (if present pretreatment) starting on or after the first dose of study drug up to 30 days after discontinuation of zanubrutinib or 90 days after discontinuation of rituximab, whichever occurred later; or initiation of new anticancer therapy if it occurred prior to the other 2 dates. Worsening of a treatment-emergent adverse event to Grade 5 beyond Day 30 after the last dose of zanubrutinib or Day 90 after the last dose rituximab was also considered a treatment-emergent adverse event if the event occurred prior to initiation of new anticancer therapy.</description>
          <population>The Safety Analysis Set included all participants who received at least 1 dose of study drug (zanubrutinib or rituximab).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants With at Least 1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 through approximately 2.5 years</time_frame>
      <desc>Participants were assessed for adverse events throughput the study and Follow-up Visit (30 days after last dose of zanubrutinib, 90 days after the last dose of rituximab, whichever occurred later). After this period, only new adverse events that were believed to be related to study treatment were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Relapsed/Refractory Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma</title>
          <description>Participants with R/R non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
        </group>
        <group group_id="E2">
          <title>Relapsed/Refractory Follicular Lymphoma</title>
          <description>Participants with R/R FL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
        </group>
        <group group_id="E3">
          <title>Relapsed/Refractory Marginal Zone Lymphoma</title>
          <description>Participants with R/R MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lymph gland infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA Version 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Haemoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information &amp; may request a further delay to protect its IP rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>BeiGene</organization>
      <phone>+1-877-828-5568</phone>
      <email>clinicaltrials@beigene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

